FIXX Homology Medicines, Inc. Stock Quote

FIXX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.74	Insider Own	0.30%	Shs Outstand	45.23M	Perf Week	-7.46%
Market Cap	482.03M	Forward P/E	-	EPS next Y	-2.67	Insider Trans	-93.73%	Shs Float	37.84M	Perf Month	-13.17%
Income	-123.10M	PEG	-	EPS next Q	-0.69	Inst Own	81.40%	Short Float	5.51%	Perf Quarter	7.98%
Sales	2.30M	P/S	209.58	EPS this Y	-26.80%	Inst Trans	-9.05%	Short Ratio	3.44	Perf Half Y	-0.94%
Book/sh	3.76	P/B	2.81	EPS next Y	7.90%	ROA	-45.30%	Target Price	-	Perf Year	-37.94%
Cash/sh	-	P/C	-	EPS next 5Y	-9.40%	ROE	-57.90%	52W Range	8.70 - 22.38	Perf YTD	-6.55%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-42.50%	52W High	-53.17%	Beta	-
Dividend %	-	Quick Ratio	10.60	Sales past 5Y	-	Gross Margin	-	52W Low	20.46%	ATR	0.81
Employees	206	Current Ratio	10.60	Sales Q/Q	50.00%	Oper. Margin	-	RSI (14)	33.58	Volatility	7.46% 6.36%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	7.50%	Profit Margin	-	Rel Volume	0.37	Prev Close	10.55
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	606.56K	Price	10.48
Recom	1.50	SMA20	-17.32%	SMA50	-16.66%	SMA200	-15.50%	Volume	221,813	Change	-0.66%

Mar-02-21

Initiated

Stifel

Hold

$14

Dec-14-20

Resumed

H.C. Wainwright

Buy

$30

Aug-11-20

Reiterated

H.C. Wainwright

Buy

$37 → $30

Jun-25-20

Resumed

BofA/Merrill

Buy

$30

May-13-20

Initiated

RBC Capital Mkts

Outperform

$30

Mar-16-20

Upgrade

Oppenheimer

Perform → Outperform

$32

Feb-24-20

Initiated

Chardan Capital Markets

Buy

$34

Nov-01-19

Initiated

Oppenheimer

Perform

Sep-10-19

Initiated

Robert W. Baird

Outperform

Apr-12-19

Initiated

Evercore ISI

Outperform

Feb-20-19

Initiated

H.C. Wainwright

Buy

$36

Jan-07-19

Initiated

Canaccord Genuity

Buy

$37

Sep-07-18

Initiated

B. Riley FBR

Neutral

$18.50

Mar-01-21 09:51AM	Homology Medicines Regains Global Rights To Novartis Ophthalmology Program Benzinga
07:30AM	Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform GlobeNewswire
Feb-25-21 08:00AM	Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences GlobeNewswire
Feb-19-21 02:30AM	What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares? Simply Wall St.
Feb-08-21 02:50PM	Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome GlobeNewswire +7.40%
Jan-06-21 08:00AM	Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II) GlobeNewswire +5.19%
Dec-14-20 01:36PM	Alexion, Calyxt, Arvinas: 5 Top Stock Gainers for Monday TheStreet.com +17.01%
Dec-11-20 07:05PM	Is FIXX A Good Stock To Buy Now? Insider Monkey
02:15PM	Oppenheimer Says These 2 Stocks Could Spike Over 100% TipRanks
Nov-25-20 10:36AM	Bausch (BHC) Begins Second Phase III Study on NOV03 for DED Zacks
Nov-10-20 03:05PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud GlobeNewswire
Nov-09-20 07:00PM	Bragar Eagel & Squire, P.C. Is Investigating Homology Medicines, Vasta Platform Limited, Tricida, and Energy Harbor and Encourages Investors to Contact the Firm GlobeNewswire
05:35PM	Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
08:00AM	Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc. GlobeNewswire
Nov-08-20 09:56AM	Reflecting on Homology Medicines' (NASDAQ:FIXX) Share Price Returns Over The Last Year Simply Wall St.
Nov-06-20 11:40AM	Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU GlobeNewswire -20.83%
Nov-05-20 09:15AM	Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU GlobeNewswire +8.79%
Nov-03-20 12:30PM	Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-20 06:50PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Investigation into Possible Securities Fraud Ongoing Newsfile
Oct-28-20 07:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX ACCESSWIRE -5.10%
Oct-27-20 06:13PM	FIXX SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud Newsfile
Oct-26-20 09:32PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Homology Medicines, Inc. FIXX GlobeNewswire
05:37PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates FIXX, TILE Investors, Encourages Investors with Losses to Contact Its Attorneys, Securities Fraud Investigations Ongoing GlobeNewswire
Oct-23-20 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX ACCESSWIRE
02:25PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates FULT, FIXX Investors, Encourages Investors with Losses to Contact Its Attorneys, SEC Finds Companies Violated Securities Laws ACCESSWIRE
Oct-22-20 04:35PM	INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE +6.43%
08:30AM	Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome GlobeNewswire
Oct-21-20 07:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX GlobeNewswire
12:26PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Newsfile
Oct-20-20 07:04PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud Newsfile
Oct-19-20 03:35PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
Oct-16-20 04:53PM	FIXX INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud Newsfile
Oct-15-20 01:33PM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
01:30PM	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
12:00PM	The Law Offices of Frank R. Cruz Continues Its Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors Business Wire
11:53AM	Rosen, A Global and Leading Law Firm, Announces an Investigation of Securities Claims Against Homology Medicines, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - FIXX Newsfile
11:30AM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors Business Wire
Oct-14-20 06:23PM	INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors Business Wire -5.55%
05:28PM	FIXX SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud GlobeNewswire
Oct-13-20 08:20PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
04:30PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors Business Wire
03:12PM	The Law Offices of Frank R. Cruz Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors Business Wire
02:55PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
01:49PM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors Business Wire
10:55AM	Rosen Law Firm Announces an Investigation of Securities Claims Against Homology Medicines, Inc. FIXX Business Wire
Oct-12-20 06:10PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud ACCESSWIRE
05:00PM	HOMOLOGY MEDICINES ALERT: Bragar Eagel & Squire, P.C. is Investigating Homology Medicines, Inc. on Behalf of Homology Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Oct-09-20 10:13PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX PR Newswire
04:15PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Homology Medicines, Inc. (FIXX) Investigation ACCESSWIRE
Oct-08-20 09:44PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud PR Newswire
Sep-18-20 09:00AM	Homology Medicines to Participate in Upcoming Conferences GlobeNewswire +9.76%
Aug-10-20 05:35PM	Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
12:39PM	We're Keeping An Eye On Homology Medicines' (NASDAQ:FIXX) Cash Burn Rate Simply Wall St.
12:38PM	Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation Simply Wall St.
Aug-06-20 12:30PM	Earnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to Decline Zacks
Jul-27-20 11:42PM	3 Strong Buy Pharma Stocks With Fast-Approaching Catalysts TipRanks
Jul-21-20 08:00AM	Homology Medicines Appoints Jeff Poulton to the Board of Directors GlobeNewswire
Jul-08-20 08:49AM	Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session Zacks -6.09%
Jun-29-20 10:49AM	Biogen and Southwest Are on the Casualty List GuruFocus.com
Jun-27-20 02:58PM	Homology Medicines, Inc. (FIXX): Hedge Funds Are Snapping Up Insider Monkey
May-26-20 02:11PM	Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program GlobeNewswire
May-19-20 04:08PM	7 Biotech Stocks Wall Street Says Will Double or More Kiplinger
May-12-20 08:00AM	Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
May-10-20 09:45AM	Homology Medicines, Inc. (NASDAQ:FIXX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
May-07-20 04:05PM	Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
Apr-29-20 08:00AM	Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting GlobeNewswire
Apr-03-20 09:44AM	Is Homology Medicines (FIXX) Stock a Solid Choice Right Now? Zacks
Mar-16-20 09:00AM	Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model GlobeNewswire -16.05%
Mar-14-20 09:14AM	Homology Medicines, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Mar-12-20 05:45PM	Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates Zacks -21.50%
04:10PM	Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments GlobeNewswire
Mar-11-20 09:22AM	Estimating The Intrinsic Value Of Homology Medicines, Inc. (NASDAQ:FIXX) Simply Wall St.
Mar-03-20 12:30PM	Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for Zacks +16.53%
Feb-20-20 09:00AM	Homology Medicines to Participate in Upcoming Investor and Scientific Conferences GlobeNewswire -5.01%
Feb-17-20 10:06AM	3 Stocks That Are Way More Expensive Than Tesla GuruFocus.com
Feb-13-20 09:00AM	Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders GlobeNewswire
Jan-31-20 11:52AM	Insiders Roundup: Texas Instruments, Homolody Medicines GuruFocus.com
Jan-14-20 08:33AM	BioMarin to Begin Early-Stage Study on Gene Therapy for PKU Zacks
Jan-13-20 02:30PM	'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment American City Business Journals
Jan-10-20 02:20PM	Cambridge startup raises $110M for re-doseable gene therapies American City Business Journals
Jan-01-20 08:01AM	We're Not Very Worried About Homology Medicines's (NASDAQ:FIXX) Cash Burn Rate Simply Wall St.
Dec-24-19 10:49AM	3 Small-Cap Stocks Ready to Make a Big Splash TipRanks
Dec-18-19 10:23AM	Homology Medicines' Gene Therapy For Phenylketonuria Found Safe, Efficacy Data Mixed Benzinga
07:23AM	The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data Benzinga
Dec-17-19 04:01PM	Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU GlobeNewswire
Dec-16-19 09:00AM	Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care GlobeNewswire +5.94%
Dec-13-19 02:44PM	Homology Medicines, Inc. (FIXX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-19 08:30AM	Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer GlobeNewswire +6.88%
Nov-26-19 03:00PM	Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs GlobeNewswire
Nov-12-19 07:35PM	Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:09PM	Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Nov-05-19 10:32AM	Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to Decline Zacks
Oct-28-19 08:07PM	Hedge Funds Have Never Been This Bullish On Homology Medicines, Inc. (FIXX) Insider Monkey
Oct-25-19 08:30AM	Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision GlobeNewswire
Oct-21-19 08:30AM	Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies GlobeNewswire
Sep-30-19 08:49AM	Homology Medicines to Participate in Conferences in October GlobeNewswire
Sep-27-19 07:37AM	Imagine Owning Homology Medicines (NASDAQ:FIXX) And Wondering If The 19% Share Price Slide Is Justified Simply Wall St.
Sep-03-19 08:30AM	Homology Medicines to Participate at Upcoming Investor Conferences GlobeNewswire

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Timothy P	See Remarks.	Mar 01	Option Exercise	4.76	4,000	19,052	6,232	Mar 03 04:05 PM
Smith W Bradford	CFO & Treasurer	Feb 08	Option Exercise	0.64	13,500	8,640	13,500	Feb 09 04:22 PM
Smith W Bradford	CFO & Treasurer	Feb 08	Sale	14.25	13,500	192,425	0	Feb 09 04:22 PM
Kelly Timothy P	See Remarks	Feb 02	Option Exercise	6.63	500	3,316	500	Feb 05 06:31 AM
Kelly Timothy P	See Remarks	Feb 02	Sale	13.00	500	6,500	0	Feb 05 06:31 AM
Kelly Timothy P	See Remarks	Feb 01	Option Exercise	4.76	4,000	19,052	4,000	Feb 03 04:05 PM
Kelly Timothy P	See Remarks	Feb 01	Sale	12.37	4,000	49,460	0	Feb 03 04:05 PM
Kelly Timothy P	See Remarks	Jan 12	Option Exercise	6.63	500	3,316	500	Jan 14 04:05 PM
Kelly Timothy P	See Remarks	Jan 12	Sale	13.00	500	6,500	0	Jan 14 04:05 PM
Seymour Albert	Chief Scientific Officer	Jan 07	Sale	12.05	5,103	61,469	129,017	Jan 08 04:05 PM
Seymour Albert	Chief Scientific Officer	Jan 06	Sale	12.06	9,897	119,395	134,120	Jan 08 04:05 PM
Seymour Albert	Chief Scientific Officer	Jan 05	Sale	11.44	10,000	114,422	144,017	Jan 07 04:05 PM
Kelly Timothy P	See Remarks	Jan 04	Option Exercise	4.76	4,000	19,052	4,000	Jan 06 04:05 PM
Kelly Timothy P	See Remarks	Jan 04	Sale	11.50	4,000	45,983	0	Jan 06 04:05 PM
PARMAR KUSH	Director	Dec 22	Sale	12.82	500,000	6,410,000	181,435	Dec 28 09:37 PM
5AM Ventures IV, L.P.	10% Owner	Dec 22	Sale	12.82	500,000	6,410,000	181,435	Dec 28 09:35 PM
PARMAR KUSH	Director	Dec 14	Sale	12.25	500,000	6,125,915	201,435	Dec 16 07:25 PM
5AM Ventures IV, L.P.	10% Owner	Dec 14	Sale	12.25	500,000	6,125,915	201,435	Dec 16 07:15 PM
Kelly Timothy P	See Remarks	Mar 17	Sale	13.01	1,315	17,109	0	Mar 18 05:32 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience